Document is current
Any future updates will be listed below
-
Authors
Boland, Patrick M. https://orcid.org/0000-0002-4213-8847
Lenz, Heinz-Josef https://orcid.org/0000-0003-2178-9568
Ciombor, Kristen K. https://orcid.org/0000-0002-5745-5909
Florou, Vaia https://orcid.org/0000-0001-5558-753X
Pishvaian, Michael J. https://orcid.org/0000-0002-1165-9041
Cusnir, Michael https://orcid.org/0000-0002-5983-980X
Cohen, Deirdre https://orcid.org/0000-0002-6178-9266
Guo, Jessie Y. https://orcid.org/0000-0001-9212-7954
Tang, Min
Rajagopalan, Prabhu https://orcid.org/0000-0003-2615-8458
Wiley, Sandra E. https://orcid.org/0000-0003-3979-2474
Ghalie, Richard G. https://orcid.org/0000-0001-6882-8179
Hochster, Howard S. https://orcid.org/0000-0002-0435-061X
- License Information
-
More Information
Article History
Received: 6 November 2024
Accepted: 12 December 2024
First Online: 27 December 2024
Declarations
:
: This study was performed in line with the ethical principles that have their origin in the Declaration of Helsinki, and the ICH Harmonised Tripartite Guideline for GCP and all applicable regulations. This study and all pertinent documents were reviewed and approved by the Institutional Review Board of each participating institution.
: All participants provided written informed consent to participate in the study prior to the initiation of any study-specific procedures.
: Patrick M. Boland is on the advisory board of AbbVie, Bristol Myers Squib, BeiGene and Taiho and has a research grant from CARIS. Kristen K. Ciombor is a consultant/advisory board for Pfizer, Incyte, Exelixis, Bayer, ALX, Tempus, Taiho, Agenus, Merck, Beigene, and has received research grants from BMS, Array, Incyte, Daiichi Sankyo, Nucana, Merck, Pfizer, Calithera, Genentech, Seagen, and Syndax. Vaia Florou is a consultant/advisory board member of Deciphera, Springwork Therapeutics, and Aadi Biosciences. Michael J. Pishvaian is a consultant/ad hoc advisory board for Astra Zeneca, Ideaya, Seattle Genetics, Merus, Merck, Moderna, Pfizer, Novartis, Astellas, and Serna Bio. He is on the Steering Committee/Advisory Board for Astellas and Merck. He has received travel, accommodations and expenses support from Astellas and RenovoRx. He owns equity in Perthera. He has received institutional research funding from Tesaro, Arcus Bio, Ideaya, Repare Tx, Novartis, Pfizer, Merck, Tizonia, Biomed Valley Discoveries, Amgen, RenovoRx, Boerhinger Ingelheim, Astellas, Hutchinson Medipharma, Takeda, Actuate, MEI Pharma, Elevation Oncology, and Recursion Pharma. Min Tang and Prabu Rajagopalan are consultants to MEI Pharma. Sandy E. Wiley and Richard G. Ghalie are employed by and hold equity in MEI Pharma. Howard S. Hochster is consultant to GSK, AstraZeneca, Processa and Compass Therapeutics, and is expert witness for Guardant. Heinz-Josef Lenz, Michael Cusnir, Dierdre Cohen, and Jessie Y. Guo have no conflicts to disclose.
